Adenocarcinoma Clinical Trial
— AVATAROfficial title:
Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation
Verified date | February 2021 |
Source | Hospital Universitario de Fuenlabrada |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas. Patients randomised to the experimental arm will undergone tumoral biopsy before starting first line of treatment and will be administered personalised therapy as second or third line.
Status | Active, not recruiting |
Enrollment | 146 |
Est. completion date | September 2022 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas. - ECOG performance status 0 or 1 - Age = 18 years old. - Willingness of male and female subjects, who are not surgically sterile or postmenopausal, to use reliable methods of birth control (oral contraceptives, intrauterine devices, or barrier methods used with a spermicide) for the duration of the study. - One or more sites of metastasis with one of the susceptible of biopsy. - Measurable or evaluable disease - No prior treatment with radiotherapy, surgery, chemotherapy or investigational treatment for the metastatic disease or no more than the three cycles of first line chemotherapy. Palliative radiotherapy for bone metastasis is allowed. Adjuvant or neoadjuvant radiotherapy or chemotherapy are allowed if they finished more that 6 months ago and the patient has no remaining toxicities. - Bone marrow function as follows, no more than 14 days prior to randomisation: ANC > 1,500 cells/mm3 Platelets > 100,000 cells/mm3 Hemoglobin =9 g/dl - Adequate liver, renal and bone marrow functions. - AST (SGOT), ALT (SGPT) = 2.5 × ULN and = 5 x ULN if liver metastases. - Bilirubin = 1,5 x ULN - Albumin total = 0,75 ULN - Creatinine = 1,5 x ULN - Ability to sign informed consent - Patients will be allowed to be randomised just once. Exclusion Criteria: - Brain metastases, unless they have been previously treated and stable for 3 months at least (defined as no oedema, no need of steroids and stable disease in two CT scans separated by a minimum of 4 weeks). - Locally advanced disease. - Malignancies other than pancreatic cancer diagnosed within 5 years prior to randomization, except for adequately treated carcinoma in situ or basal or squamous cell skin cancer. - Bacterial, viral or fungal active infection that require systemic treatment. - Any contraindication for tumor biopsy. - Past or present HIV or hepatitis B or C infection. - Severe medical problems affecting organs or psychiatric illnesses that could interfere with the safety of the patient in the trial. - Pregnancy or breastfeeding women. - Patient will need to be informed and agree to undergo tumoral biopsy in the experimental arm. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario de Fuenlabrada | Fuenlabrada | Madrid |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario de la Paz | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Hospital Miguel Servet | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitario de Fuenlabrada |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1-year overall survival | Efficacy. 1-year overall survival | 1-year overall survival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT02125240 -
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
Completed |
NCT01579721 -
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
|
Phase 4 | |
Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00548548 -
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
|
Phase 3 | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00183859 -
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
|
Phase 1 | |
Recruiting |
NCT01930864 -
Metformin Plus Irinotecan for Refractory Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02498860 -
Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 |